Baillie Gifford & Co’s VYNE Therapeutics VYNE Stock Holding History

Baillie Gifford & Co’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,487	Closed	-$65K	–	511
2022 Q1	$65K	Hold	5,487	–	–	﹤0.01%	299
2021 Q4	$101K	Hold	5,487	–	–	﹤0.01%	297
2021 Q3	$138K	Hold	5,487	–	–	﹤0.01%	280
2021 Q2	$347K	Hold	5,487	–	–	﹤0.01%	272
2021 Q1	$676K	Hold	5,487	–	–	﹤0.01%	264
2020 Q4	$624K	Hold	5,487	–	–	﹤0.01%	254
2020 Q3	$655K	Hold	5,487	–	–	﹤0.01%	244
2020 Q2	$683K	Buy	5,487 +3,682	+204%	+$499K	﹤0.01%	227
2020 Q1	$349K	Buy	+1,805	New	+$566K	﹤0.01%	210

Other funds holding VYNE

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Baillie Gifford & Co's VYNE Position: Q2 2022 in Review

Baillie Gifford & Co sold out of VYNE Therapeutics (VYNE) in Q2 2022, closing a stake of 5,487 shares — an estimated $65K sold.

Baillie Gifford & Co first reported a position in VYNE in Q1 2020 and held it in 9 quarters. The position peaked at $683K in Q2 2020. 41 funds tracked by Wall St. Rank hold VYNE as of Q2 2022.

Baillie Gifford & Co reported no remaining VYNE Therapeutics position as of Q2 2022 after selling out during the quarter.
Baillie Gifford & Co sold 5,487 VYNE Therapeutics shares in Q2 2022, an estimated $65K.
Baillie Gifford & Co first reported a position in VYNE Therapeutics in Q1 2020 and held it in 9 quarters.
Baillie Gifford & Co's VYNE Therapeutics position peaked at $683K in Q2 2020.
41 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2022.

Based on Baillie Gifford & Co's 13F filing for Q2 2022, filed 8 Aug 2022.